News & Publications

March 4, 2024

Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications

Audion Therapeutics BV announced today, together with the REGAIN consortium the publication of the results from a Phase I/IIa trial of an intratympanically administered gamma-secretase inhibitor (LY3056480) as a drug treatment for acquired sensorineural hearing loss (ISRCTN number 59733689).

February 5, 2019

Audion Therapeutics and REGAIN Consortium Announce Positive Phase I Results in Patients with Sensorineural Hearing Loss

The REGAIN consortium, led by Audion Therapeutics BV, a company dedicated to the development of therapeutics for hearing loss, today reports positive results from its Phase I multiple ascending dose, open-label safety study of the Notch Inhibitor LY3056480 in 15 patients with mild to moderate sensorineural hearing loss (SNHL)…

September 7, 2015

Audion Therapeutics Raises Funds to Advance the Development of Hearing Loss Treatment

Audion Therapeutics announced today that it has received a 2.5 million Euro Series B investment from INKEF Capital, a Netherlands based venture capital firm. In addition, Audion announced that, together with a strong international consortium of development partners, it was awarded a 5.8 million Euro grant through the Horizon 2020 program…

February 10, 2014

Audion Announces Investment and Licensing Deal With Lilly To Develop Hearing Loss Treatments

Audion Therapeutics announced today that it has received a Series A investment from Eli Lilly and Company to enable the company to progress its programs targeting sensorineural hearing loss. As part of the investment, the parties also entered into a licensing agreement that gives Audion the rights to certain Lilly compounds that can be developed to potentially treat hearing loss by hair cell regeneration…

June 16, 2011

Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics (Audion) to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach…